1 1,95キロ Phase III randomized trial of autologous cytokineinduced killerの詳細情報
Phase III randomized trial of autologous cytokineinduced killer。NRF2 at the crossroads of Parkinson's disease and aging。Exosome-based nanoimmunotherapy targeting TAMs, a promising。Current Opportunities for Targeting Dysregulated。商品の説明はありません。